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ABSTRACT 
 
 
 
 Type 1 and Type 2 diabetic patients experience prolonged hyperglycemia punctuated by 
short episodes of hypoglycemia.  These patients develop diabetic complications, which involves 
loss of normal tissue function. Cell death via the endoplasmic reticulum (ER) stress pathway in 
response to nutrient availability is a potential mechanism underlying these complications.  To 
understand glucose’s role in ER stress in vivo, we induced hypo- and hyper-glycemia in 
zebrafish embryos, and analyzed normal development and CHOP/GADD153 expression, a major 
component of ER stress signaling.  
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BACKGROUND 
Diabetes 
 Diabetes is a metabolic disorder that affects the body's ability to produce and use insulin, 
a hormone that is necessary to maintain normal levels of glucose in the circulation.  Prolonged 
exposure to dysregulated glucose can lead to many complications including blindness, heart 
disease, kidney failure, cardiovascular disease, and degeneration of peripheral nerves.  Diabetes 
is caused by impaired insulin secretion in pancreatic beta cells, and/or a reduced insulin efficacy 
(resistance) in muscle, adipose, and liver (Figure-1).  
 
Figure 1:  Role of Pancreatic Insulin Regulating Blood Glucose Levels.  
Diagram shows the pancreas (yellow) secreting insulin (green), which induces 
the uptake of glucose in the liver (diagram left) or skeletal muscle (diagram 
right).  In the absence of insulin (diagram center) glucose uptake is reduced, 
increasing its levels in the blood (red, diagram lower). 
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Approximately 16 million Americans are affected by Type 1, or juvenile diabetes; it is 
the more severe form of this illness, and is caused by autoimmune destruction of one’s insulin-
producing beta cells. Type 1 diabetes is known as a complex trait disease as mutations in several 
different genes contribute to this disease.  For example, because of the recent mapping of the 
genome, we know that the insulin-dependent diabetes mellitus (IDDM1) locus on chromosome 6 
may hold at least one susceptibility gene for Type 1 diabetes (National Center for Biotechnology 
Information, 2007).  It is unclear how a mutation at this locus adds to patient risk, although the 
region’s gene map includes genes for antigens that normally tell the immune system not to attack 
itself.  In Type 1 diabetes, the body's immune system recognizes its own pancreatic beta cells as 
foreign, and triggers an immunological assault on the insulin and the pancreatic cells that 
manufacture it. However, it is unsure how this mechanism actually works (National Center for 
Biotechnology Information, 2007).  Currently, about 10 loci in the human genome have been 
correlated with Type 1 diabetes (National Center for Biotechnology Information, 2007). Among 
these include a gene at the locus IDDM2 on chromosome 11, and the gene for glucokinase 
(GCK) on chromosome 7, an enzyme that is important to glucose metabolism that helps 
modulate the secretion of insulin. 
Type 2 diabetes, or adult onset/noninsulin-dependent diabetes, is the most common form 
of diabetes.  In Type 2 patients, the defects in glucose homeostasis can exist within the 
pancreatic beta cell to cause it to not secrete sufficient insulin or the defect can exist in peripheral 
tissues, such as adipose tissue, liver, and muscle, which may not respond properly to insulin.  
This latter effect is termed “insulin resistance”, and can result in from a disruption of the signal 
transduction pathway needed for insulin to upregulate glucose transporters on the cell surface 
(American Diabetes Association, 2010).  Glucose transporters, such as GLUT-1 normally bind 
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glucose to transport it inside cells.  If liver or muscle cells are defective, insulin cannot 
upregulate GLUT on the cell surface, so glucose does not enter cells for energy or storage, but 
remains in the blood stream causing hyperglycemia.  Family history and genetics play a large 
role in type 2 diabetes (American Diabetes Association, 2010).  Low physical activity, poor diet, 
and excess body weight (especially around the waist) significantly increase risk for type 2 
diabetes.                                                                                                                                                                                                                                                                                                                                                                     
 
Hypoglycemia 
 Although the hallmark symptom of diabetes is hyperglycemia, diabetic patients also 
experience hypoglycemia, or low blood sugar, especially when too much insulin is injected.  In 
studies performed by the American Diabetes Association, when type 1 diabetics and 
nondiabetics were normalized for hyperinsulenima, type 1 diabetic patients experienced more 
severe and prolonged hypoglycemia (Bolli, 1999).  According to the study, rather than being 
insulin-sensitive, the subjects’ hypoglycemia can better be explained by their compromised 
counterregulatory defenses (Bolli, 1999).  The mechanism of the compromised counterregulatory 
defenses could be explained by two defects.  The first defect, and most common, is the loss of 
glucagon response to hypoglycemia which is irreversible (Bolli, 1999). Glucagon is a hormone 
secreted by the pancreas which raises blood glucose levels, the opposite effect of insulin. When 
blood glucose levels fall low, the pancreas releases glucagon which causes the liver to convert 
glycogen into glucose. Glucose also stimulates the release of insulin, thus its loss of a response to 
it would result in a lack of productivity in the feedback system that keeps glucose levels at the 
right level (American Diabetes Association, 2010).  
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In the second defect, patients experience reduced responses to adrenaline, another 
counterregulatory hormone.  This hormone normally acts to regulate the sympathetic nervous 
system, thus reduced responses to it would cause a lack of accuracy in response to “fight or 
flight” situations.  This loss of adrenaline response is usually due to short-term antecedent 
“recurrent iatrogenic hypoglycemia”, and is less often seen during long-term diabetes (Bolli, 
1999). 
 
Hyperglycemia 
 Hyperglycemia, the hallmark diabetic symptom, is defined as high blood sugar.  During 
digestion, carbohydrates are broken down into sugar molecules. Glucose is the main energy 
source for the body, and it enters the blood stream immediately to travel to all parts of the body 
to provide an energy source.  However, glucose cannot leave the bloodstream and enter tissues in 
need of energy without the help of insulin, which binds the insulin receptor to stimulate signal 
transduction pathways that upregulate glucose transporter molecules to the cell surface.  Under 
conditions of insufficient insulin secretion, or of insufficient insulin-induced upregulation of 
GLUT, glucose remains in the blood resulting in hyperglycemia (Staff, 2010).   
 Normoglycemic blood sugar levels are approximately 110 milligrams per deciliter 
(mg/dL or 6 mmol/mL).  Patients with hyperglycemia have blood sugar levels of 200 mg/dL, or 
11 mmol/L (Staff, 2010).  At this threshold, patients start to experience symptoms of 
hyperglycemia.  Early signs of the condition are fatigue, frequent urination, increased thirst, 
headache, and blurred vision (Staff, 2010).  Prolonged hyperglycemia can result in ketones (toxic 
acids) building up in the blood and urine, to cause nausea, vomiting, abdominal pain, weakness, 
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confusion, and coma (Staff, 2010).  If untreated, hyperglycemia can create severe complications 
for a patient. 
 
Diabetic Complications 
 When left untreated, or when undiagnosed, hyperglycemia has severe complications, 
possibly affecting every organ in the body.  The eyes are often affected early in the disease.  For 
example, patients can develop glaucoma or cataracts.  Diabetics are 40% more likely to develop 
glaucoma than nondiabetics, as pressure builds in the anterior chamber to pinch blood vessels 
carrying blood to the retina and optic nerve (American Diabetes Association, 2010).  The nerve 
damage causes loss of vision.  Also, diabetics are sixty percent more likely to develop cataracts 
than nondiabetics; they develop them sooner in life, and they are more severe (American 
Diabetes Association, 2010).  Additionally, diabetics are at risk for cardiovascular disease, 
neuropathy, nephropathy, and peripheral arterial disease (American Diabetes Association, 2010). 
 Some complications of hyperglycemia put diabetics at risk of death.  When a patient 
develops diabetic ketoacidosis, there is not enough insulin in the bloodstream for the body to 
break down glucose for energy, so instead the body begins to break down adipose tissue, which 
releases ketone acids into the blood.  This toxin floods the circulatory system, and eventually 
spills over into the urinary tract.  If untreated, ketoacidosis can lead to a diabetic coma or death 
(Staff, 2010). 
 Another emergency complication of diabetes is diabetic hyperosmolar syndrome.  In this 
condition, neither glucose nor adipose can be broken down for energy.  Blood glucose levels 
become significantly increased, glucose is flushed into the urine, and the patient experiences 
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increased urination.  Without treatment, the patient becomes extremely dehydrated which can be 
fatal, or else the patient may experience a diabetic coma (Staff, 2010). 
 
Endoplasmic Reticulum Stress 
Excessive loss of pancreatic beta cells, whether due to autoimmunity or to cell functional 
collapse, is a main cause of diabetes.  Apoptosis is the main mode of pancreatic beta cell death 
(Oyadomari & Mori, 2004).  One characteristic of pancreatic beta cells is a highly developed 
endoplasmic reticulum (ER) secretion capacity, especially involving insulin.  The ER has many 
important functions, including post translational modification, folding, and assembly of newly 
synthesized secretory proteins.  Its proper function is essential to the survival of cells (Araki et 
al., 2003).   In order for proteins to perform proper cell functions, they need to be folded into 
their proper conformations. Unfolded or misfolded proteins are harmful to cell survival.  Protein 
misfolding in the ER is termed “ER stress”.  ER stress is present in both physiological and 
pathological conditions. Physiological ER stress includes tissue ischemia and neuronal 
excitotoxicity.  In natural cell injuries, ER stress is one of many components that disrupt the 
cell’s homeostasis (Zinszner, et al., 1998).  Increasing evidence indicates that pancreatic beta cell 
death in diabetes may result from increased ER stress (Harding and Ron, 2002). 
In order for the cell to overcome this stress, the ER has a specific signaling pathway, 
known as the ER stress response pathway, or the unfolded protein response (UPR), which 
involves at least three different signaling responses (Wang et al., 2010).  
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Translational Attenuation 
An early part of the UPR response is known as translational attenuation (Figure-2, 
upper diagram).  This response reduces the load of new protein synthesis in the ER to help 
prevent the accumulation of unfolded proteins in the lumen.  In the event of ER Stress, 
PERK (one of the ER kinase sensors) is activated (not shown in the figure), which 
phosphorylates eukaryotic initiation factor-2 (eIF2) to halt the manufacture of new proteins 
(Wang et al., 2010).  This PERK-mediated attenuation initiates a “survival signal” to stop 
the influx of newly synthesized proteins in the ER lumen to reduce the ER workload.   
  
  
 
Figure 2:  ER Stress and Apoptosis.  Diagram shows the balance between 
various ER stress pathways that tend to increase cell survival versus apoptosis 
pathways that lead to cell death.  These pathways are thought to be important in 
beta cell death in diabetes.  (Oyadomari and Mori, 2004) 
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Induction of Stress Response Genes 
In the next phase of the UPR, several groups of genes are transcriptionally induced to 
provide long-term adaptation to ER stress (diagram center).  This new synthesis of stress-induced 
proteins escapes the general translational attenuation.  In order for the ER to accommodate 
unfolded proteins, ER chaperones are induced to first try to refold them, and if this refolding 
response does not work then other components are introduced to degrade the unfolded or 
misfolded proteins.  In addition, transcription factor NFκB is activated to induce an inflammation 
response to increase cell survival (diagram center right).  
Considerable research has focused on the mechanism of chaperone production.  IRE1α is 
self-activated by autophosphorylation.  This endoribonuclease removes a 26 nucleotide intron 
from X-box binding protein-1 (XBP1) pre-mRNA.  This splicing creates a frameshift to allow 
the translation of a functional bZIP transcription factor (Wang et al., 2010).  The spliced bZIP 
transcription factor activates the expression of ER chaperones and enzymes which work to 
relieve the ER stress by facilitating protein folding, maturation, and secretion (Wang et al., 
2010).   Transcription factor ATF6 upregulates the expression of chaperones Bip/GRP78 and 
GRP94.  ATF6 leaves the ER membrane to relocate to the Golgi apparatus.  The Golgi processes 
ATF6 with proteases which produces and active bZIP transcription factor, which as described 
above activates expression of UPR target genes (Wang et al., 2010).  
 
Cellular Apoptosis 
If ER stress continues, eventually apoptosis signaling pathways are activated (diagram 
right side).  At least three apoptosis pathways that are known to be involved, including the 
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activation of CHOP, JNK kinase, and caspase-12.  At this point, the decision between survival 
and cell death depends on the balance between cell survival signaling versus apoptosis signaling.   
 
CHOP and ER Stress 
 CHOP activation is of special interest to this MQP project.  CHOP is a 29 kDa protein 
consisting of 169 amino acids in humans, and 168 residues in rodents.  CHOP was the first 
protein to be identified as a dominant-negative inhibitor of the C/EBP family of proteins 
(Oyadomari & Mori, 2004). CHOP is also known as the growth arrest- and DNA damage 
inducible gene 153 (GADD153).  GADD genes are a group of genes induced by toxic stress and 
growth arrest signals. These proteins form a family of transcription factors known to regulate a 
variety of genes involved in many physiological processes, including immune functions, cell 
differentiation, and proliferation (Oyadomari & Mori, 2004).  CHOP is composed of an N-
terminal transactivation domain (Figure-3) and a C-terminal bZIP domain, the latter contains a 
DNA-binding basic region and a leucine zipper dimerization region. The basic region contains 
conserved glycine (109) and proline (112) residues, which are essential for binding to the 
consensus C/EBP-binding site. Two serine residues (79 and 82) in the transactivation domain are 
phosphorylated by p38 MAP kinase, and this phosphorylation is required for the enhanced 
transcriptional activation of CHOP-induced genes.  
 
Figure 3: Domain Structure of Human CHOP/GADD153 Protein.  CHOP consists of an N-
terminal transactivation domain, and a C-terminal domain containing a C/EBP-binding basic 
domain and a leucine zipper dimerization domain.  (Oyadomari and Mori, 2004) 
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Under ER stress conditions, chaperone BiP binds to unfolded proteins and activates stress 
transducers including PERK, ATF6, and Ire1 (Figure-4). Activated PERK phosphorylates 
eIF2α, which results in translational induction of ATF4 (diagram left). During ER stress, the 
transcriptional induction of CHOP is regulated at least by four cis-acting elements, AARE1, 
AARE2, ERSE1 and ERSE2. ATF4, pATF6 (N) and XBP-1. 
 
 
Figure 4:  Transcriptional Induction of CHOP during ER Stress.  ER stress is 
known to induce apoptotic CHOP expression via at least three known pathways, 
including PERK (diagram left), ATF6 (diagram center), and IRE1 (diagram 
right).  Oyadomari and Mori, 2004) 
 
 Recent publications have tried to correlate the relationship of CHOP with ER stress. 
Since the precise mechanism by which ER stress induces CHOP is not known, studies have tried 
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to demonstrate that the CHOP induction signal originates from the ER itself, and is not just a 
downstream consequence of impaired ER function (Zinszner, et al., 1998).  CHOP undergoes a 
stress-induced phosphorylation by members of the p38-MAP kinase family to activate the 
protein.  CHOP has been shown to be nuclear, and able to form stable heterodimers with C/EBP 
relatives.  The dimers are able to recognize DNA target sequences to alter gene expression.  
 Experiments have also shown that CHOP can be induced by specific pharmacological 
agents such as tunicamycin (an inhibitor of protein glycosylation) and thapsigargin (an ER-
specific calcium ATPase inhibitor) (Zinszner, et al., 1998).  Cells that lack CHOP (CHOP -/-) 
have a normal ER stress response.  Normal cells, and cells with temperature sensitive mutations 
in essential components of the ER glycosylation apparatus, were cultured with tunicamycin.  In 
normal cells treated with tunicamycin, the chop gene is induced to high levels, but is 
undetectable in chop-/- cells.  It was also determined that induction of the ER chaperone Bip is 
indistinguishable in the two cell populations. This indicates that CHOP is not required for the 
initial ER stress response, so perhaps CHOP is required for the subsequent induction of 
apoptosis.  These authors concluded that the absence of CHOP promotes increased survival of 
cells exposed to ER stress. These authors also concluded that CHOP does not appear to have an 
important role in cell-cycle arrest in response to tunicamycin (Zinszner, et al., 1998).  
 These findings are important to our project because it is necessary to determine how cells 
respond when ER stress is induced with a pharmacological agent.  
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PROJECT PURPOSE 
 
 Our lab is focused on the influence of the metabolic environment on pancreas and general 
embryo development.  In mammals, both hypo- and hyper-glycemia are known to induce cellular 
stress responses and apoptosis, both of which are mediated by CHOP/GADD153.  The purpose 
of this project was to investigate the developmental consequences of manipulating endogenous 
glucose levels in zebrafish embryos in vivo, and linking this to CHOP/GADD153 expression, as 
well as to embryonic growth and morphology. 
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METHODS 
 
Semi-Quantitative RT-PCR 
CHOP primers were designed to run with RNA samples from 10 different embryos. This 
RT-PCR test represented the embryos exposed to hypoglycemic conditions and their controls.  
The PCR machine was set to run at an annealing temperature of 57°C for 31 cycles, with a 32 
second extension time.  The resulting samples were run on a 1% agarose gel.  Particularly of 
interest was the effect of treating 72 hour embryos with 3-mercaptopicolinic acid (MPA) versus 
the MPA control; this should demonstrate whether hypoglycemic conditions affected the 
expression of CHOP.  MPA is an agent that blocks gluconeogenesis, thus inducing 
hypoglycemia.   
 
In Situ Hybridization  
Whole embryo in situ hybridizations were performed on 24.5 and 72 hour old embryos, 
with one embryo set that was treated with 2.0 mM MPA, and one set as the MPA control, to 
determine the expression of CHOP at each stage during development.  Two probes designed 
against the CHOP gene were made and tested by using two different restriction enzymes: SpeI 
and Not1.  SpeI restriction enzyme cut the RNA expression plasmid to express RNA from the T7 
promoter; Not1 cuts the expression plasmid to express RNA from the Sp6 promoter.  These 
“riboprobes” were digoxygenin-labeled synthesized from the expression plasmids in vitro, and 
were used to identify CHOP-expressing tissues under hypo- and hyper-glycemic conditions. 
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Figure 5: In Situ Hybridization Schematic.  This figure depicts the process of in situ 
hybridization.  The substrate, BM purple, is dephosphorylated by the enzyme alkaline 
phosphatase present in the antibody detecting the digoxigenin-labeled RNA probe, 
allowing the chemifluorescence to show where the CHOP gene is expressed in the 
embryo. 
 
 
Glucose Measurements 
Groups of 20-25 screened embryos were recounted and transferred to 1.5ml 
microcentrifuge tubes.  Embryo lysates were cleared by centrifugations, and stored at -80°C.  
Reactions were assembled on ice with reagents purchased from Biovision. The standard curves 
for glucose were generated using the Biovision standard solution, according to the instructions 
provided.  Glucose measurements in embryo extracts were performed by adding 8 µl of sample 
to 42 µl of assay buffer.  50 µl of reaction mix containing 1 µl enzyme solution, and 0.4 µl 
glucose probe were added.  Reactions were incubated at 37°C for 30 min in the dark, and 
fluorescence was measured using a Safire II plate reader equipped with ZFLUOR4 software (v 
4.51), specific for free glucose.  Glucose levels were estimated from standard curves, and 
measured in triplicate.  
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RT-PCR, Ligation, Transformation 
Sample RNA was measured in the treated and control samples on a nanodrop 
spectrophotometer.  Our control sample measured 273.43 ng/µl, and our treated sample 
measured 188.26 ng/µl. We used these measurements to determine the amount of RNA needed 
to run our RT-PCR.  
For CHOP RT-PCR, the oligonucleotides used were ZfchopF1qRT102809 with the 
sequence AGTTGGAGGCGTGGTATGA, and ZfchopR1qRT102809 with the sequence 
AGATCTCCGGATGAGGTGTT.  The optimal annealing temperature for these oligonucleotides 
was 57.4°C with a length of 256 bp.  We ran the RT-PCR program in the thermocycler for 35 
cycles, and stored the amplified samples in a -20°C freezer.  
We then used our amplified CHOP RT-PCR amplicons to clone into plasmid PCRII 
(Invitrogen) using TA cloning in which the 3’ A tail on the amplicon is annealed to the 3’ T-tail 
on the plasmid (Figure-6).  The RT-PCR amplicon, PCR II vector, ligation buffer, and DNA 
ligase were combined to run in the thermocycler on the Ligation program, which ran overnight.  
 
            
             
 
Figure 6:  Cloning of CHOP into Plasmid PCRII.  This figure shows the construction of the 
plasmid that was used in order to successfully transform our cloned products into the competent E. 
coli cells.  The 3’ A-tail on the amplicon is directly annealed to the 3’ T-tail on the vector.  
Nucleotides thymine and adenine are represented because it accurately depicts how our cloned 
product was inserted into the vector. 
 
 
BACTERIA 
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In order to transform our cloned products we performed the following steps.  We thawed 
the competent cells (One Shot® TOP10 Chemically Competent E. coli, also Invitrogen) and 
added an aliquot of the ligation reaction to the cells, while gently swirling to mix the two.  After 
the cells were incubated on ice for 30 minutes, we added 0.5 mL of SOC medium and allowed 
the cells to grow at 37°C for 1 hour. After the cells incubated, we spun them down and removed 
the medium, leaving about 30 µl so we could resuspend the cells in the remaining medium. We 
then aseptically transferred the cells to an amp+ plate, spread the cells with a glass spreader, and 
allowed the plate to incubate overnight at 37°C.  
After the cells had incubated overnight, we isolated and grew four bacterial colonies in 
50mL falcon tubes. We aseptically selected four different colonies that were large and isolated to 
avoid satellite colonies, and put them in the falcon tubes containing 10 mL of Lennox broth. 
These four samples were then put in the incubator at 37°C for one hour, after which we 
performed a midi-plasmid preparation using the protocol from Midi Plasmid Preparation Kit 
(UM-100) from Boston BioProducts, Inc.  
After the plasmid preparation was complete, we measured all four samples in the 
nanodrop spectrophotometer to see which colony had the highest yield.  Colony 1 yielded 336.86 
ng/µl, Colony 2 yielded 290.25 ng/µl, Colony 3 yielded 320.74 ng/µl, and Colony 4 yielded 
334.75 ng/µl.  Using colony 1, we split the sample into two equal aliquots, and digested the 
plasmid with two restriction enzymes, SpeI and NotI that would allow us to access the promoters 
of interest, T7 and Sp6.  
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RESULTS 
 
 
 
 This project focused on the effects of hyper- and hypoglycemic conditions in developing 
zebrafish embryos.   Both types of glycemic conditions trigger an ER stress response and 
apoptosis, which is mediated by CHOP/GADD153.  The project monitored the expression of 
CHOP/GADD153 in response to manipulation of varying glucose environments.  In Figure 7, a 
CHOP RT-PCR was performed on RNA samples from wild type embryos ranging from 16 to 96 
hours post fertilization.  The RT-PCR CHOP oligonucleotides used were 270 bp in length. The 
CHOP amplicon is represented by the lowest (and strongest) of the three bands shown.  It is 
evident that CHOP is upregulated at each stage of development assayed. The band increases in 
intensity from left to right, allowing us to deduce that CHOP is expressed at each developmental 
checkpoint.  
 
 
Figure 7: Expression of CHOP at Various Stages of Development.  Semi-
quantitative RT-PCR was performed on 16, 24, 48, 72, and 96 hour samples 
wild type for CHOP expression.  They were run against a 100bp ladder (not 
shown, see next figure) to demonstrate that they were in fact CHOP.  The CHOP 
amplicon is represented by the strong lowest band in each lane.  The figure 
shows that at each stage of development, CHOP is upregulated because of the 
increasing intensity of the bands. 
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 Following this experiment we ran another RT-PCR monitoring the effects of a 
gluconeogenesis inhibitor, MPA, on CHOP expression in the 72 hour embryo.  As seen in 
Figure 8, lane-1 shows CHOP in the control embryo, while lane-2 shows CHOP levels in 
embryos treated with MPA.  It appears that CHOP expression is slightly increased in the MPA-
treated RNA sample, although not by a significant amount. 
 
Figure 8:  RT-PCR Analysis of CHOP Expression at 72 Hours in the 
Presence of a Gluconeogenesis Inhibitor (MPA).  Semi-quantitative RT-PCR 
was performed on 2 mM MPA-treated and MPA-control embryos.  This figure 
shows that CHOP expression was slightly upregulated in the MPA-treated 
samples, though it was still present in control samples.  The CHOP amplicon 
was expected at 270 bp, corresponding to the lowest of the 3 bands, and the 
presence of two other larger bands was unexpected and considered “junk” 
bands. 
 
 Figure 9 shows the in situ hybridization procedure performed on the 72 hour MPA 
control embryos (riboprobe prepared from the T7 promoter).  CHOP expression is seen below 
the eyes (arrows).  There was no inhibition of gluconeogenesis in this control embryo, yet there 
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is still ample expression of CHOP.  Thus, even in normoglycemia, cells are being sent down the 
apoptosis pathway, mediated by CHOP. 
 
 
Figure 9:  CHOP In Situ Hybridization, Dorsal View of 72 Hour MPA-
Control.  The probe used was CHOPT7.   
 
 
Figure 10 shows a dorsal view of two 72 hour embryos probed for CHOP mRNA 
through in situ hybridization under control and MPA conditions.  One embryo is treated with 
MPA to block gluconeogenesis (right panel), while the control was not treated (left panel).  Both 
the control and MPA treated samples showed patterns of CHOP expression beneath the eyes, and 
surprisingly the intensity of the staining was similar, implying similar amounts of CHOP 
expression. 
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Figure 10: CHOP In Situ Hybridization, Lateral View of 72 Hour Embryos.  Probe was 
CHOPT7.   (Left) Control embryo.  This image shows CHOP expression below the eyes even 
when gluconeogenesis is not inhibited.  When gluconeogenesis is blocked by MPA (Right), the 
BM purple in situ probe should dye darker in the embryo to indicate more CHOP expression in 
these stressful conditions. However, this was not the case as the 2mM treated embryo showed 
similar staining patterns and intensity. 
 
 
 Figure-11 shows photographs of general embryo morphology after incubation with 3-
MPA between the two to eight cell stage for 24 hours.  The MPA treatment (right panel) does not 
appear to affect the rate of growth or morphological development compared to control (left 
panel).   This figure shows us that there is no obvious phenotypic difference in early 
development when exposed to different glycemic environments.  
 
Figure 11:  Photography of Zebrafish Embryos To Assay General Morphology Affected by 
MPA.  There is no obvious morphological effect of the MPA treatment (right panel) compared to 
control embryos (left panel).  e, eye; fb, forebrain; hb, hindbrain; mhb, midbrain-hindbrain 
boundary; s, somite. 
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 Figure 12 shows that 3-MPA causes a dose-dependent decrease in total embryonic 
glucose for embryos analyzed at 22 hours post fertilization. This is significant because it 
confirms that MPA is indeed creating a hypoglycemic environment. 
 
 
Figure 12:  Analysis of Normal and MPA-Treated Embryo 
Glucose Levels.  3-MPA causes a dose-dependent reduction in total 
embryonic glucose.  Embryos were analyzed at 22 hours post-
fertilization.  
 
 
Additional experiments involving more stages of embryo development showed that the 
treatment with 1.5 mM 3-MPA (the highest dose used in the previous figure) caused a 10-fold 
reduction in free glucose back to levels normally seen in 8-cell embryos (Figure-13). This 
suggests that pathways other than gluconeogenesis do not compensate for the loss of normal, 
embryonic glucose accumulation at this stage (22 hours post-fertilization).   
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Figure 13:  Assay of Picomoles of Glucose per 
Zebrafish Embryo at Different Developmental 
Stages Under Normal Conditions.  Note the 
high levels of glucose present in 24 hr embryos. 
 
 
 
 
 
 
 Pck1 is a regulator of gluconeogenesis so we also analyzed its expression in early 
embryos (Figure 14).  At 24 hour post fertilization (left image), pck1 is expressed in the 
developing eye and tail.  At 72 hours (right image), expression in the liver is seen (see lowercase 
letter “l” in right figure below).  This Pck1 expression is very similar to the pattern of expression 
of CHOP, seen in previous in situ hybridization images. These images show the effect of a 
normal hyperglycemic environment on pck1 in the embryos at 24 and 72 hours post fertilization.  
 
 
Figure 14:   PCK1 In Situ Hybridization.  Shown are 24 hr (left) and 72 hr 
(right) embryos, demonstrating pck1 expression at each stage.  Arrows in the 
right image denote expression in the yolk syncytial layer. 
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The levels of pck1 were also quantitated at different stages of development (Figure-15).  
This analysis shows that at developmental stages from 16-cells to 16 hours post-fertilization 
(first 3 histobars), when embryo glucose levels are low and insulin b levels are high, pck1 levels 
are low.  At 24 hours post fertilization, when glucose levels are high and there are low levels of 
insulin b while the levels of insulin a increase, pck1 levels begin increasing.  Finally, between 48 
and 120 hours post-fertilization, when glucose levels are low and insulin a levels are high, pck1 
levels are also high.  Thus, at very early stages of Zebrafish development, there is an inverse 
correlation between pck1 and insulin levels, but a direct correlation later in development.  This 
differs from adult mammals where pck1 expression is inhibited by insulin (Quinn & Yeagley, 
2005).  In the zebrafish embryo, pck1 is not expressed at early stages, when non-pancreatic insb 
mRNA is abundant and glucose is very low. 
 
 
 
Figure 15:  Levels of pck1 mRNA During Zebrafish Development.  Y-axis 
denotes levels of pck1 mRNA. Histobars denote means of 3 independent 
experiments.  Error bars denote standard error. 
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DISCUSSION 
 
 
In our lab, the focus is on monitoring the effects of the metabolic environment on 
Zebrafish embryos during development.  In this project, embryos were exposed to MPA to 
induce hypoglycemic conditions, and the effects on ER stress marker CHOP/GADD153 
expression were observed.  It was our hypothesis that CHOP would be upregulated in both 
hypoglycemic and hyperglycemic conditions (as in diabetes) and down regulated in normal 
conditions, because the apoptosis pathway would be necessary to destroy stressed cells.  We 
observed CHOP expression below the eyes in normal embryos, and when gluconeogenesis was 
blocked, CHOP expression slightly increased to initiate the apoptosis pathway of diabetic cells, 
as expected.  Thus, even when gluconeogenesis is not blocked, the CHOP apoptosis pathway is 
still being used by the embryo.  This implies that glucose does not regulate CHOP because it is 
seen in similar pattern and intensity regardless of glycemic conditions. 
We also assayed the levels of embryonic pck1.  Pck1 is an enzyme that stimulates 
gluconeogenesis (to elevate blood glucose), which is the opposite of MPA which creates a 
hypoglycemic environment.  Pck1 mRNA expression was seen in the eye, tail, and liver.  An in 
situ hybridization (see Figure 14) shows the expression of pck1 at different stages of 
development.  The data indicated that the pattern of pck1 regulation, as well as intensity of its 
expression, is similar to the pattern and intensity of expression of CHOP.  Again, this implies 
that glucose may not regulate CHOP.  It was expected that production of glycogen and the 
apoptosis pathway would not be seen in the same cells.  As stated by Wang, under ER stress, 
there is translational attenuation so that more proteins are not produced incorrectly; eventually 
CHOP is regulated to destroy cells under ER stress.  The presence of pck1 while there is also ER 
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stress (CHOP) implies that glucose is not the effector causing ER stress and apoptosis; 
otherwise, pck1 production would be stopped to cease ER stress. 
General embryo morphology was also analyzed under control and hypoglycemic 
conditions (MPA).  We hypothesized that treatment of zebrafish embryos with 3-
mercaptopicolinic acid (3-MPA) would show phenotypic abnormalities, as being deprived of a 
main energy source during the first 24 hours of development should theoretically be detrimental 
to the embryo.  However, we observed no obvious phenotypic differences.   This implies that 
glucose, besides not being important for CHOP regulation, may also not be important for early 
development. 
A study performed by Carayannopoulos et al. (2004) also studied the effects of 
compromising glucose metabolism on mouse development.  Their data showed that the glucose 
transporter GLUT9 is crucial in preimplantation development in mice.  Mice without GLUT9, or 
with defective transporters, had increased pregnancy loss (Carayannopoulos et al., 2004).  So if 
in mice glucose transporters are critical for development, this implies glucose is important in 
mouse development, so why the difference with Zebrafish.  Importantly, Caryannopoulos noted 
that blocking GLUT9 did not kill embryos until transfer back into the womb.  Since zebrafish 
embryos are never transported back to the womb, perhaps a similar glucose-dependent survival 
phenomenon is not witnessed in zebrafish. 
For future studies, the effects of lack of glucose in embryos need to be examined on long 
term Zebrafish development.  While we did not see any obvious phenotypic differences at 24 
hours, it is crucial to determine whether differences appear later in development, and if so what 
is their severity.  Also, it is critical to see when the embryo starts to depend on the presence of 
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glucose; thus it should be examined whether the lack or surplus of glucose too early or too late in 
development puts the embryo at risk for diabetes. 
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